Ingredient Safety

Today, CHPA announced a new initiative to support retailers in states that have adopted laws prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan to minors. The announcement comes on the heels of Nevada’s enactment of a DXM age-restriction law last week.

To combat teen abuse of over-the-counter (OTC) medicines containing the cough suppressant dextromethorphan (DXM), Oregon Governor Kate Brown today signed legislation prohibiting the sale of DXM-containing products to minors.

This week, Nevada Governor Brian Sandoval signed legislation prohibiting the sale of over-the-counter (OTC) medicines containing the cough suppressant dextromethorphan (DXM) to minors.

A newly published article in the medical journal Pediatrics concludes that over-the-counter (OTC) cough and cold medicines for children are safe when used and stored as directed.

“The results of this year’s Monitoring the Future survey demonstrate that prevention through education works,” Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville said.

A recent study conducted by Charles River Associates, a leading global consulting firm, has quantified the savings consumers and the healthcare system receive from the over-the-counter (OTC) availability of the widely used cough suppressant dextromethorphan (DXM).

Substance Abuse Treatment, Prevention, and Policy recently published a case study authored by CHPA about the association’s efforts to curb teen abuse of OTC cough medicine containing dextromethorphan.

CHPA released the following statement today in support of a Delaware law prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan (DXM) to minors.

Unlike other drugs subject to user fees, nonprescription drugs under the Monograph system are not subject to FDA approval prior to marketing. Many of these ingredients have been marketed for more than 40 years, with a long history of safe use. We must define value differently than industries subject to FDA approval prior to marketing.